Exhibit 4.2


 


Execution Version 


 


Sagimet
Biosciences Inc.


 


AMENDED AND RESTATED


investors’
rights agreement


 


This
Amended and Restated Investors’ Rights Agreement (this “Agreement”) is made as of December
21, 2020, by and among Sagimet Biosciences Inc., a Delaware corporation (the
 “Company”), and the investors listed on the Schedule of Investors attached as Exhibit A hereto
(each, an “Investor,” and collectively, the “Investors”).


 


Whereas,
the Company and the certain Investors are purchasing shares of the Company’s Series F Preferred Stock (the “Series F
Preferred”) pursuant to that certain Series F Preferred Stock Purchase Agreement (the “Purchase
Agreement”) dated on or about the date hereof, as amended from time to time (the “Financing”);


 


Whereas,
certain of the Investors (the “Prior Investors”) are holders of the Company’s Series
A Preferred Stock (“Series A Preferred”), Series A’ Preferred Stock (“Series A’
Preferred”), Series B Preferred Stock (“Series B Preferred”), Series B’ Preferred
Stock (“Series B’ Preferred”), Series B-1 Preferred Stock (“Series B-1 Preferred”),
Series B-1’ Preferred Stock (“Series B-1’ Preferred”), Series C Preferred Stock (“Series
C Preferred”), Series C’ Preferred Stock (“Series C’ Preferred”), Series D
Preferred Stock (“Series D Preferred”), Series D’ Preferred Stock (“Series D’
Preferred”), Series D-1 Preferred Stock (“Series D-1 Preferred”) and Series E Preferred
Stock (the “Series E Preferred”);


 


Whereas,
the Prior Investors and the Company are parties to that certain Amended and Restated Investors’ Rights Agreement dated February
12, 2019 (the “Prior Agreement”);


 


Whereas,
in order to induce the Company to enter into the Purchase Agreement and to induce certain Investors to invest funds in the Company
pursuant to the Purchase Agreement, the Investors and the Company hereby agree that this Agreement shall govern the rights of the
Investors to cause the Company to register shares of the Company’s Common Stock (“Common Stock”)
issuable to the Investors upon the conversion of the Preferred Stock and certain other matters as set forth herein;


 


Whereas,
the parties to the Prior Agreement desire to amend and restate the Prior Agreement and accept the rights and covenants hereof
in lieu of their rights and covenants under the Prior Agreement, and the undersigned parties constitute the parties necessary to
amend and restate the Prior Agreement in its entirety; and


 


Whereas,
in connection with the consummation of the Financing, the Company and the Investors have agreed to the registration
rights, information rights, and other rights as set forth below.


 


Now,
Therefore, the parties hereto hereby agree that, effective as of the Initial Closing (as defined in the Purchase Agreement),
the Prior Agreement shall be amended and restated in its entirety by this Agreement, which shall supersede and replace the Prior
Agreement, and further agree as follows:


 


1.            
Restrictions on Transferability; Registration Rights. The Company covenants and agrees as follows:


 


1.1           Definitions.
For purposes of this Agreement:


 


(a)                “Change
of Control” means each of the following events: (i) any consolidation or merger of the Company with or into any
other corporation or other entity or person, or any other corporate reorganizations, provided that the applicable transaction
shall not be deemed a Change of Control unless the Company’s stockholders constituted immediately prior to such transaction
do not hold more than fifty percent (50%) of the voting power of the surviving or acquiring entity (or its parent) immediately
following such transaction (taking into account only voting power resulting from stock of the Company held by such stockholders
prior to such transaction); (ii) any transaction or series of related transactions to which the Company is a party in which in
excess of fifty percent (50%) of the Company’s voting power outstanding before such transaction is transferred; or (iii)
a sale, conveyance or other disposition by the Company or any subsidiary of the Company, in a single transaction or series of
related transactions, of all or substantially all of the assets of the Company and its subsidiaries taken as a whole (including
without limitation a license by the Company or any subsidiary of the Company of all or substantially all of the Company’s
or such subsidiary’s, as the case may be, intellectual property that is either exclusive or otherwise structured in a manner
that constitutes a license of all or substantially all of the assets of the Company and its subsidiaries taken as a whole) or
the sale or disposition (whether by merger or otherwise) of one or more subsidiaries of the Company if substantially all of the
assets of the Company and its subsidiaries taken as a whole are held by such subsidiary or subsidiaries, except where such sale,
lease, transfer, exclusive license or other disposition is to a wholly owned subsidiary of the Company; provided that a Change
of Control shall not include (x) a merger or consolidation with a wholly-owned subsidiary of the Company, (y) a merger effected
exclusively for the purpose of changing the domicile of the Company or (z) any transaction or series of related transactions principally
for bona fide equity financing purposes in which the Company is the surviving corporation.


 






     
 


     


    

 


(b)                “Common
Warrants” means those certain warrants to purchase Common Stock issued pursuant to that certain Series C Preferred
Stock Purchase Agreement dated June 14, 2013 by and among the Company and the purchasers listed on Exhibit A thereto.


 


(c)                “Exchange
Act” means the Securities Exchange Act of 1934, as amended, or any similar successor federal statute, and the rules
and regulations thereunder, all as the same shall be in effect from time to time.


 


(d)                “Form
S-3” means such form under the Securities Act as in effect on the date hereof or any registration form under the
Securities Act subsequently adopted by the SEC that permits inclusion or incorporation of substantial information by reference
to other documents filed by the Company with the SEC.


 


(e)                “GAAP”
shall have the meaning set forth in Section 3.1(a) hereto.


 


(f)                 “Holder”
means any person owning or having the right to acquire Registrable Securities or any assignee thereof in accordance with Section
1.12 of this Agreement.


 


(g)                “IPO”
means the first public offering of the Common Stock of the Company to the general public that is effected pursuant to a registration
statement filed with, and declared effective by, the SEC under the Securities Act.


 


(h)                “Preferred
Stock” means collectively the Series A Preferred, the Series A’ Preferred, the Series B Preferred, the Series
B’ Preferred, the Series B-1 Preferred, the Series B-1’ Preferred, the Series C Preferred, the Series C’ Preferred,
the Series D Preferred, the Series D’ Preferred, the Series E Preferred and the Series F Preferred. For the avoidance
of doubt, Preferred Stock shall not include the Series D-1 Preferred.


 


(i)                 “Qualified
IPO” shall have the meaning given in the Restated Certificate.


 



    2


     


    

 





(j)                 The
terms “register,” “registered” and “registration”
refer to a registration effected by preparing and filing a registration statement or similar document in compliance with the Securities
Act, and the declaration or ordering of effectiveness of such registration statement or document.


 


(k)               “Registrable
Securities” means (i) Common Stock of the Company issuable or issued upon conversion of the Preferred Stock of the
Company and (ii) any Common Stock issued or issuable (directly
or indirectly) upon conversion and/or exercise of
any other securities of the Company acquired by the Investors,
including upon exercise of the Common Warrants.


 


(l)                 The
number of shares of “Registrable Securities then outstanding” shall be the sum of the number of shares
of Common Stock outstanding that are, and the number of shares of Common Stock issuable pursuant to then exercisable or convertible
securities that are, Registrable Securities.


 


(m)              “Restated
Certificate” shall mean the Company’s Tenth Amended and Restated Certificate of Incorporation, as may be amended
from time to time.


 


(n)               “Restricted
Securities” shall mean the securities of the Company required to bear the legend set forth in Section 1.2 hereof.


 


(o)               “SEC”
shall mean the Securities and Exchange Commission.


 


(p)               “Securities
Act” means the Securities Act of 1933, as amended, or any similar successor federal statute, and the rules and regulations
thereunder, all as the same shall be in effect from time to time.


 


(q)               “Shares”
shall have the meaning set forth in Section 3.4 hereto.


 


(r)               “Voting
Agreement” shall have the meaning given in the Purchase Agreement.


 


1.2          Restrictions
on Transferability.


 


(a)                The
holder of each certificate representing Shares and Registrable Securities by acceptance thereof agrees to comply in all respects
with the provisions of this Section 1.2. Each Holder agrees not to make any sale, assignment, transfer, pledge or other disposition
of all or any portion of the Restricted Securities, or any beneficial interest therein, unless and until (x) the transferee thereof
has agreed in writing for the benefit of the Company to take and hold such Restricted Securities subject to, and to be bound by,
the terms and conditions set forth in this Agreement, including, without limitation, this Section 1.2 and Section 2, and (y):


 


(i)                There
is then in effect a registration statement under the Securities Act covering such proposed disposition and such disposition is
made in accordance with such registration statement; or


 


(ii)              Such
Holder shall have given prior written notice to the Company of such Holder’s intention to make such disposition and shall
have furnished the Company with a detailed description of the manner and circumstances of the proposed disposition, and, if requested
by the Company, such Holder shall have furnished the Company, at its expense, with (i) an opinion of counsel, reasonably satisfactory
to the Company, to the effect that such disposition will not require registration of such Restricted Securities under the Securities
Act or (ii) a “no action” letter from the SEC to the effect that the transfer of such securities without registration
will not result in a recommendation by the staff of the SEC that action be taken with respect thereto, whereupon the holder of
such Restricted Securities shall be entitled to transfer such Restricted Securities in accordance with the terms of the notice
delivered by the Holder to the Company. It is agreed that the Company will not require prior written notice, opinions of counsel
or “no action” letters from the SEC for transactions made pursuant to Rule 144 of the Securities Act (“Rule
144”).





 



    3


     


    




 


(b)                Permitted
transfers include (i) transfers not involving a change in beneficial ownership, or (ii) transfers of Restricted Securities by
any Holder to (x) a parent, subsidiary or other affiliate of Holder, or (y) any of its partners, members or other equity owners,
or retired partners, retired members or other equity owners, or to the estate of any of its partners, members or other equity
owners or retired partners, retired members or other equity owners, or (iii) transfers in compliance with Rule 144, as long as
the Company is furnished with satisfactory evidence of compliance with such rule, if requested; provided, in each case, that the
Holder thereof shall give written notice to the Company of such Holder's intention to effect such disposition and shall have furnished
the Company with a detailed description of the manner and circumstances of the proposed disposition. For the avoidance of doubt,
the Preferred Stock is freely transferable, subject to applicable laws and the transferee executing required joinders.


 


(c)                Each
certificate representing Shares or Registrable Securities shall (unless otherwise permitted by the provisions of this Agreement)
be stamped or otherwise imprinted with a legend substantially similar to the following (in addition to any legend required under
applicable state securities laws):

 


“THE SHARES
REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE SOLD, TRANSFERRED, ASSIGNED,
PLEDGED, OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER SUCH ACT, OR UNLESS THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL OR
OTHER EVIDENCE, IF REQUESTED, SATISFACTORY TO THE COMPANY AND ITS COUNSEL, THAT SUCH REGISTRATION IS NOT REQUIRED.”


 


“THE SHARES
REPRESENTED HEREBY MAY BE TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF AN INVESTORS’ RIGHTS AGREEMENT BETWEEN THE COMPANY
AND THE STOCKHOLDER, A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY.”


 


The Holders consent to
the Company making a notation on its records and giving instructions to any transfer agent of the Restricted Securities in order
to implement the restrictions on transfer established in this Section 1.2.


 


(d)                The
first legend referring to federal and state securities laws identified in Section 1.2(c) hereof stamped on a certificate evidencing
the Restricted Securities and the stock transfer instructions and record notations with respect to such Restricted Securities
shall be removed and the Company shall issue a certificate without such legend to the holder of such Restricted Securities if
(i) such securities are registered under the Securities Act, (ii) such holder provides the Company with an opinion of counsel
reasonably acceptable to the Company to the effect that a public sale or transfer of such securities may be made without registration
under the Securities Act, or (iii) such holder provides the Company with reasonable assurances, which may, at the option of the
Company, include an opinion of counsel satisfactory to the Company, that such securities can be sold pursuant to Rule 144 under
the Securities Act.


 






    4


     


    




 


1.3           Request
for Registration.


 


(a)                 Subject
to the conditions of this Section 1.3, if the Company shall receive at any time after the earlier of the date that is (i) three
(3) years after the date of this Agreement or (ii) six months following the effective date of the registration statement pertaining
to the IPO, a written request pursuant to this Section 1.3 from Holders of at least 35% of the Registrable Securities then
outstanding (assuming conversion of all Preferred Stock and exercise of the Common Warrants) (the “Initiating Holders”)
that the Company file a registration statement under the Securities Act covering the registration of Registrable Securities which
would have an aggregate offering price of not less than $5,000,000, the Company shall within twenty (20) days of the receipt thereof,
give written notice of such request to all Holders, and subject to the limitations of this Section 1.3, use its best efforts to
effect, as soon as practicable, the registration under the Securities Act of all Registrable Securities that the Holders request
to be registered in a written request received by the Company within twenty (20) days of the mailing of the Company’s notice
pursuant to this Section 1.3(a).


 


(b)                If
the Initiating Holders intend to distribute the Registrable Securities covered by their request by means of an underwriting, they
shall so advise the Company as a part of their request made pursuant to Section 1.3(a) and the Company shall include such information
in the written notice referred to in Section 1.3(a). The underwriter will be selected by the Company and shall be reasonably acceptable
to a majority in interest of the Initiating Holders. In such event, the right of any Holder to include its Registrable Securities
in such registration shall be conditioned upon such Holder’s participation in such underwriting and the inclusion of such
Holder’s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their
securities through such underwriting shall enter into an underwriting agreement in customary form with the underwriter or underwriters
selected for such underwriting. Notwithstanding any other provision of this Section 1.3, if the underwriter determines in
good faith that marketing factors require a limitation of the number of shares to be underwritten, then the Company shall so advise
all Holders of Registrable Securities which would otherwise be underwritten pursuant hereto, and the number of shares of Registrable
Securities that may be included in the underwriting shall be allocated, first, to the Initiating Holders on a pro rata
basis based on the total number of Registrable Securities held by the Initiating Holders; and second, to any Holder on a pro
rata basis among all such Holders; provided, however, that if as a result of any such cutback fewer than fifty-percent
(50%) of the total number of Registrable Securities that have been requested by Holders of Registrable Securities to be included
in such registration statement are actually included, than such registration statement shall not be counted as “effected”
for purposes of this Section 1.3 (including for purposes of Section 1.3(d)(i)), notwithstanding the obligation of the Company
to proceed with the offering.


 


(c)                Notwithstanding
the foregoing, if the Company shall furnish to the Holders requesting a registration statement pursuant to this Section 1.3 a
certificate signed by the Chief Executive Officer of the Company (“Chief Executive Officer”) stating
that, in the good faith judgment of the Board of Directors of the Company (the “Board of Directors”),
it would be materially detrimental to the Company and its stockholders for such registration statement to be filed and it is therefore
essential to defer the filing of such registration statement, then the Company shall have the right to defer taking action with
respect to such filing for a period of not more than ninety (90) days after receipt of the request of the Initiating Holders;
provided, however, that the Company may not utilize this right more than once in any twelve (12) month period; and, provided,
further, that the Company shall not register any securities for its own account or that of any other stockholders during such
ninety (90) day period other than (i) a registration relating to the sale of securities to employees of the Company or a subsidiary
pursuant to a stock option, stock purchase, or similar plan; (ii) a registration relating to an SEC Rule 145 transaction; (iii)
a registration on any form that does not include substantially the same information as would be required to be included in a registration
statement covering the sale of the Registrable Securities; or (iv) a registration in which the only Common Stock being registered
is Common Stock issuable upon conversion of debt securities that are also being registered.


 



    5


     


    

 





(d)            In
addition, the Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to this Section
1.3:


 


(i)          after
the Company has effected two (2) registrations pursuant to this Section 1.3 and such registrations have been declared or ordered
effective;


 


(ii)         during
the six-month period following the effective date of the registration statement pertaining to the IPO; or


 


(iii)        if,
within thirty (30) days of a registration request by the Initiating Holders, the Company gives notice to the Holders of its
intent to file a registration statement for its IPO within ninety (90) days.


 


1.4           Company
Registration.


 


(a)                 If
(but without any obligation to do so) the Company proposes to register (including for this purpose a registration effected by
the Company for stockholders other than the Holders) any of its stock or other securities under the Securities Act in connection
with the public offering of such securities solely for cash (other than a registration relating solely to the sale of securities
to participants in a Company stock plan, any registration statements relating to any corporate reorganization or transaction under
Rule 145 of the Securities Act or any registration statements related to the issuance or resale of securities issued in such a
transaction or a registration in which the only Common Stock being registered is Common Stock issuable upon conversion of debt
securities which are also being registered), the Company shall, at such time, promptly give each Holder written notice of such
registration. Upon the written request of each Holder given within ten (10) days after mailing of such notice by the Company in
accordance with Section 5.6, the Company shall, subject to the provisions of Section 1.4(b), cause to be registered under the
Securities Act all of the Registrable Securities that each such Holder has requested to be registered. Registrations effected
pursuant to this Section 1.4 shall not be counted as demands for registration pursuant to Section 1.3 or registrations pursuant
to Section 1.5.


 


(b)                 If
the registration statement under which the Company gives notice under this Section 1.4 is for an underwritten offering, the Company
shall so advise the Holders of Registrable Securities. In such event, the right of any such Holder to be included in a registration
pursuant to this Section 1.4 shall be conditioned upon such Holder’s participation in such underwriting and the inclusion
of such Holder’s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute
their Registrable Securities through such underwriting shall enter into an underwriting agreement in customary form with the underwriter
or underwriters selected for such underwriting by the Company. Notwithstanding any other provision of this Agreement, if the underwriter
determines in good faith that marketing factors require a limitation of the number of shares to be underwritten, the number of
shares that may be included in the underwriting shall be allocated, first, to the Company; second, to the Holders on a pro
rata basis based on the total number of Registrable Securities held by the Holders; and third, to any stockholder of the Company
(other than a Holder) on a pro rata basis. No such reduction shall reduce the amount of securities of the selling Holders
included in the registration below twenty-five percent (25%) of the total amount of securities included in such registration,
unless such offering is the IPO and such registration does not include shares of any other selling stockholders, in which event
any or all of the Registrable Securities of the Holders may be excluded in accordance with the immediately preceding sentence.
For any Holder which is a partnership or corporation, the partners, retired partners and shareholders of such Holder, or the estates
and family members of any such partners and retired partners and any trusts for the benefit of any of the foregoing persons shall
be deemed to be a single “Holder,” and any pro rata reduction with respect to such “Holder” shall
be based upon the aggregate amount of shares carrying registration rights owned by all entities and individuals included in such
 “Holder,” as defined in this sentence.


 






    6


     


    




 


(c)                The
Company shall have the right to terminate or withdraw any registration initiated by it under this Section 1.4 prior to the effectiveness
of such registration whether or not any Holder has elected to include securities in such registration.


 


1.5           Form
S-3 Registration. In case the Company shall receive from any Holders of a majority of the then outstanding Registrable Securities
(assuming conversion of all Preferred Stock and exercise of the Common Warrants) a written request or requests that pursuant to
this Section 1.5 the Company effect a registration on Form S-3 and any related qualification or compliance with respect to all
or a part of the Registrable Securities owned by such Holder or Holders, the Company will:


 


(a)               promptly
give written notice of the proposed registration, and any related qualification or compliance, to all other Holders; and


 


(b)               use its best efforts to effect such registration and all such qualifications and compliances as may be so requested
and as would permit or facilitate the sale and distribution of all or such portion of such Holders’ Registrable Securities
as are specified in such request, together with all or such portion of the Registrable Securities of any other Holders joining
in such request as are specified in a written request given within fifteen (15) days after receipt of such written notice from
the Company; provided, however, that the Company shall not be obligated to effect any such registration, qualification or
compliance, pursuant to this Section 1.5: (i) if Form S-3 is not available for such offering by the Holders; (ii) if the Holders
propose to sell Registrable Securities and such other securities (if any) at an aggregate price to the public of less than $1,000,000;
(iii) if, in a given twelve-month period, the Company has already effected two (2) such registrations pursuant to this Section
1.5 in such period; (iv) if the Company shall furnish to the Holders a certificate signed by the President of the Company stating
that in the good faith judgment of the Board of Directors, it would be materially detrimental to the Company and its stockholders
for such registration statement to be filed and it is therefore essential to defer the filing of such registration statement, in
which event the Company shall have the right to defer the filing of the Form S-3 registration statement for a period of not more
than ninety (90) days after receipt of the request of the Holder or Holders under this Section 1.5; provided, however, that
the Company shall not utilize this right more than once in any twelve (12) month period; or (v) in any particular jurisdiction
in which the Company would be required to qualify to do business or to execute a general consent to service of process in effecting
such registration, qualification or compliance or otherwise subject itself to general taxation. Subject to the foregoing, the Company
shall file a registration statement covering the Registrable Securities and other securities so requested to be registered as soon
as practicable after receipt of the request or requests of the Holders. Registrations effected pursuant to this Section 1.5 shall
not be counted as demands for registration effected pursuant to Section 1.3.


 


1.6           Obligations
of the Company.  Whenever required under this Section 1 to effect the registration of any Registrable Securities, the
Company shall, as expeditiously as reasonably possible:


 


(a)                 Prepare
and file with the SEC a registration statement with respect to such Registrable Securities and use its best efforts to cause such
registration statement to become effective, and, upon the request of the Holders of a majority of the Registrable Securities registered
thereunder, keep such registration statement effective for a period of up to 120 days, or if earlier, until the distribution contemplated
in the registration statement has been completed.


 






    7


     


    

 





(b)                Prepare
and file with the SEC such amendments and supplements to such registration statement and the prospectus used in connection with
such registration statement as may be necessary to comply with the provisions of the Securities Act with respect to the disposition
of all securities covered by such registration statement.


 


(c)                Furnish
to the Holders of Registrable Securities registered thereunder such numbers of copies of a prospectus, including a preliminary
prospectus, in conformity with the requirements of the Securities Act, and such other documents as they may reasonably request
in order to facilitate the disposition of Registrable Securities owned by them.


 


(d)                Use
its best efforts to register and qualify the securities covered by such registration statement under such other securities or
Blue Sky laws of such jurisdictions as shall be reasonably requested by the Holders of Registrable Securities registered thereunder;
provided, that the Company shall not be required in connection therewith or as a condition thereto to qualify to do business
or to file a general consent to service of process, or subject itself to general taxation, in any such states or jurisdictions.


 


(e)                In
the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual
and customary form, with the managing underwriter of such offering. Each Holder of Registrable Securities registered thereunder
participating in such underwriting shall also enter into and perform its obligations under such an agreement.


 


(f)                Notify
each Holder of Registrable Securities covered by such registration statement at any time when a prospectus relating thereto is
required to be delivered under the Securities Act or the happening of any event as a result of which the prospectus included in
such registration statement, as then in effect, includes an untrue statement of a material fact or omits to state a material fact
required to be stated therein or necessary to make the statements therein not misleading in the light of the circumstances then
existing.


 


(g)               Cause
all such Registrable Securities registered pursuant hereunder to be listed on each securities exchange or nationally recognized
quotation system on which similar securities issued by the Company are then listed.


 


(h)               Provide
a transfer agent and registrar for all Registrable Securities registered pursuant hereunder and a CUSIP number for all such Registrable
Securities, in each case not later than the effective date of such registration.


 


(i)                Cooperate
in all necessary respects with (A) counsel in preparation of the customary legal opinions and (B) accountants in preparation of
the customary comfort letters, copies of which shall be provided to each Holder of Registrable Securities registered thereunder
so requesting; provided that such Holders shall not be entitled to rely upon such legal opinions and comfort letters other than
in accordance with their own respective terms.


 


(j)                Promptly
make available for inspection by the Holders of Registrable Securities registered thereunder, any managing underwriter(s)
participating in any disposition pursuant to such registration statement, and any attorney or accountant or other agent
retained by any such underwriter or selected by the Holders of Registrable Securities registered thereunder, all financial and
other records, pertinent corporate documents, and properties of the Company, and cause the Company’s officers, directors,
employees, and independent accountants to supply all information reasonably requested by any such seller, underwriter, attorney,
accountant, or agent, in each case, as necessary or advisable
to verify the accuracy of the information in such registration statement and to conduct appropriate due diligence in connection
therewith.


 






    8


     


    

 





1.7           Furnish
Information.


 


(a)                 It
shall be a condition precedent to the obligations of the Company to take any action pursuant to this Section 1 with respect to
the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding itself,
the Registrable Securities held by it, and the intended method of disposition of such securities as shall be required to effect
the registration of such Holder’s Registrable Securities.


 


(b)                 The
Company shall have no obligation with respect to any registration requested pursuant to Section 1.3 or Section 1.5 if, due to
the operation of Section 1.7(a), the number of shares of the Registrable Securities to be included in the registration does
not equal or exceed the number of shares required to originally trigger the Company’s obligation to initiate such registration
as specified in Section 1.3(a) or Section 1.5(b), as the case may be.


 


1.8           Expenses
of Registration. All expenses, other than underwriting discounts, transfer taxes and commissions incurred by the selling Holders
in connection with registrations, shall be paid or reimbursed by the Company for filings or qualifications pursuant to Section
1.3, Section 1.4 and Section 1.5, including (without limitation) all registration, filing and qualification fees, printers’
and accounting fees, fees and disbursements of counsel for the Company and the reasonable fees and disbursements of one counsel
for the selling Holders (collectively, the “Registration Expenses”); provided, however, that
the Company shall not be required to pay for any Registration Expenses of any registration proceeding begun pursuant to Section
1.3(a) or Section 1.5 if the registration request is subsequently withdrawn at the request of the Holders of a majority of the
Registrable Securities to be registered unless (a) the withdrawal is based upon material adverse information concerning the Company
of which the Initiating Holders or Holders, as applicable, were not aware at the time of such request or (b) the Holders of a
majority of Registrable Securities to be registered agree to deem such registration to have been effected as of the date of such
withdrawal for purposes of determining whether the Company shall be obligated pursuant to Section 1.3 to undertake any subsequent
registration, in which event such right shall be forfeited by all Holders. If the Holders are required to pay the Registration
Expenses, such expenses shall be borne pro rata based upon the number of Registrable Securities that were to be registered
in the withdrawn registration.


 


1.9           Delay
of Registration. No Holder shall have any right to obtain or seek an injunction restraining or otherwise delaying any such
registration as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 1.


 


1.10        Indemnification.
In the event any Registrable Securities are included in a registration statement under this Section 1:


 


(a)                 To
the fullest extent permitted by law, the Company will indemnify and hold harmless each Holder, the partners, members, officers,
directors, stockholders and former stockholders of each Holder, any underwriter (as defined in the Securities Act) for such Holder
and each person, if any, who controls such Holder or underwriter within the meaning of the Securities Act or the Exchange Act,
against any losses, claims, damages or liabilities (joint or several) to which they may become subject under the Securities Act,
the Exchange Act or other federal or state law, insofar as such losses, claims, damages or liabilities (or actions in respect
thereof) arise out of or are based upon any of the following statements, omissions or violations (collectively a “Violation”):
(i) any untrue statement or alleged untrue statement of a material fact contained in such registration statement, including any
preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto, (ii) the omission or alleged
omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading,
or (iii) any violation or alleged violation by the Company of the Securities Act, the Exchange Act, any state securities law or
any rule or regulation promulgated under the Securities Act, the Exchange Act or any state securities law; and the Company will
pay to each such Holder, underwriter or controlling person any legal or other expenses reasonably incurred by them in connection
with investigating or defending any such loss, claim, damage, liability or action, as such expenses are incurred; provided,
however, that the indemnity agreement contained in this Section 1.10(a) shall not apply to amounts paid in settlement of any
such loss, claim, damage, liability or action if such settlement is effected without the consent of the Company (which consent
shall not be unreasonably withheld), nor shall the Company be liable in any such case for any such loss, claim, damage, liability
or action to the extent that it arises out of or is based upon a Violation which occurs in reliance upon and in conformity with
written information relating to any such Holder and furnished expressly for inclusion in a registration statement in connection
with such registration by such Holder, the partners, members, officers, directors and stockholders of such Holder, the underwriter
for such Holder or a controlling person of such Holder and; provided further, however, that the foregoing indemnity agreement
with respect to any preliminary prospectus shall not inure to the benefit of any Holder, partners, members, officers, directors
and stockholders of any Holder, or any underwriter for such Holder, or any person controlling such Holder, from whom the person
asserting any such losses, claims, damages or liabilities purchased shares in the offering, if a copy of the prospectus (as then
amended or supplemented) was not sent or given by or on behalf of such Holder or underwriter to such person, if required by law
so to have been delivered by such Holder, at or prior to the written confirmation of the sale of the shares to such person, and
if the prospectus (as so amended or supplemented) would have cured the defect giving rise to such loss, claim, damage or liability.


 






    9


     


    

 





(b)                To
the extent permitted by law, each selling Holder, severally, and not jointly, will indemnify and hold harmless the Company, each
of its directors, each of its officers who has signed the registration statement, each person, if any, who controls the Company
within the meaning of the Securities Act, any underwriter, any other Holder selling securities in such registration statement
and any controlling person of any such underwriter or other Holder, against any losses, claims, damages or liabilities to which
any of the foregoing persons may become subject, under the Securities Act, the Exchange Act or other federal or state law, insofar
as such losses, claims, damages or liabilities (or actions in respect thereto) arise out of or are based upon any Violation, in
each case to the extent (and only to the extent) that such Violation occurs in reliance upon and in conformity with written information
relating to such Holder and furnished by such Holder expressly for use in connection with such registration; and each such Holder
will pay any legal or other expenses reasonably incurred by any person intended to be indemnified pursuant to this Section 1.10(b),
in connection with investigating or defending any such loss, claim, damage, liability or action; provided, however, that
the indemnity agreement contained in this Section 1.10(b) shall not apply to amounts paid in settlement of any such loss,
claim, damage, liability or action if such settlement is effected without the consent of the Holder, which consent shall not be
unreasonably withheld, provided that in no event shall any indemnity under this Section 1.10(b) exceed the net proceeds from
the offering received by such Holder (including net of any underwriting discounts, selling commissions, and stock transfer taxes
applicable to the sale of Registrable Securities).


 


(c)                Promptly
after receipt by an indemnified party under this Section 1.10 of notice of the commencement of any action (including any
governmental action), such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party
under this Section 1.10, deliver to the indemnifying party a written notice of the commencement thereof and the indemnifying party
shall have the right to participate in, and, to the extent the indemnifying party so desires, jointly with any other indemnifying
party similarly noticed, to assume the defense thereof with counsel mutually satisfactory to the parties; provided, however,
that an indemnified party (together with all other indemnified parties which may be represented without conflict by one counsel)
shall have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if representation
of such indemnified party by the counsel retained by the indemnifying party would be inappropriate due to actual or potential
differing interests between such indemnified party and any other party represented by such counsel in such proceeding. The failure
to deliver written notice to the indemnifying party within a reasonable time of the commencement of any such action, if prejudicial
to its ability to defend such action, shall relieve such indemnifying party of any liability to the indemnified party under this
Section 1.10, but the omission to so deliver written notice to the indemnifying party will not relieve it of any liability that
it may have to any indemnified party otherwise than under this Section 1.10.


 






    10


     


    

 





(d)                If
the indemnification provided for in this Section 1.10 is held by a court of competent jurisdiction to be unavailable to an indemnified
party with respect to any loss, liability, claim, damage or expense referred to therein, then the indemnifying party, in lieu
of indemnifying such indemnified party hereunder, shall contribute to the amount paid or payable by such indemnified party as
a result of such loss, liability, claim, damage or expense in such proportion as is appropriate to reflect the relative fault
of the indemnifying party on the one hand and of the indemnified party on the other in connection with the statements or omissions
that resulted in such loss, liability, claim, damage or expense as well as any other relevant equitable considerations; provided,
that, in no event shall any contribution under this Section 1.10(d) by a Holder exceed the net proceeds from the offering received
by such Holder (including net of any underwriting discounts, selling commissions, and stock transfer taxes applicable to the sale
of Registrable Securities). The relative fault of the indemnifying party and of the indemnified party shall be determined by reference
to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission to state a material
fact relates to information supplied by the indemnifying party or by the indemnified party and the parties’ relative intent,
knowledge, access to information and opportunity to correct or prevent such statement or omission.


 


(e)                Notwithstanding
the foregoing, to the extent that the provisions on indemnification and contribution between the Company and underwriter contained
in the underwriting agreement entered into in connection with the underwritten public offering are in conflict with the foregoing
provisions, the provisions in the underwriting agreement shall control.


 


(f)                The
obligations of the Company and Holders under this Section 1.10 shall survive the completion of any offering of Registrable
Securities in a registration statement under this Section 1.


 


1.11        Reports
Under Securities Exchange Act of 1934. With a view to making available to the Holders the benefits of Rule 144 promulgated
under the Securities Act and any other rule or regulation of the SEC that may at any time permit a Holder to sell securities of
the Company to the public without registration or pursuant to a registration on Form S-3, the Company agrees to:


 


(a)                make
and keep public information available, as those terms are understood and defined in Rule 144, at all times after ninety (90) days
after the effective date of the IPO;


 


(b)                file
with the SEC in a timely manner all reports and other documents required of the Company under the Securities Act and the Exchange
Act; and


 



    11


     


    





 


(c)               furnish
to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i) a written statement by the Company
that it has complied with the reporting requirements of Rule 144 (at any time after ninety (90) days after the effective date
of the first registration statement filed by the Company), the Securities Act and the Exchange Act (at any time after it has become
subject to such reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant to Form
S-3 (at any time after it so qualifies), (ii) a copy of the most recent annual or quarterly report of the Company and such other
reports and documents so filed by the Company, and (iii) such other information as may be reasonably requested in availing any
Holder of any rule or regulation of the SEC which permits the selling of any such-securities without registration or pursuant
to such form.


 


1.12         Assignment
of Registration Rights. The rights to cause the Company to register Registrable Securities pursuant to this Section 1 may
be assigned (but only with all related obligations) by (i) a Holder that is a partnership, to any partner, retired partner or
affiliated fund of such Holder, (ii) a Holder that is a limited liability company or a corporation, to any member or former member
or stockholder of such Holder, (iii) a Holder who is an individual, to such Holder’s family member or trust for the benefit
of such Holder or such Holder’s family member, (iv) a Holder that transfers all shares of Registrable Securities held by
he, she or it, or (v) to any other person acquiring at least 500,000 shares (or not less than all of such Holder’s Registrable
Securities, if such Holder holds less than 500,000 Registrable Securities) (as appropriately adjusted for any stock split, dividend,
combination or other recapitalization or like transactions) of Registrable Securities; provided (in all cases) (a) the Company
is, promptly after such transfer, furnished with written notice of the name and address of such transferee or assignee and the
securities with respect to which such registration rights are being assigned; (b) such transferee or assignee agrees in writing
to be bound by and subject to the terms and conditions of this Agreement, including without limitation the provisions of Section
2 below; and (c) such assignment shall be effective only if immediately following such transfer the further disposition of such
securities by the transferee or assignee is restricted under the Securities Act.


 


1.13         
Termination of Registration Rights. All registration rights granted under this Section 1 shall terminate and be of no
further force and effect upon the earlier of (i) four (4) years after the consummation of the IPO, or (ii) the effective date
of a Change of Control pursuant to which the Holders receive cash or securities traded on a nationally recognized securities exchange.
In addition, a Holder’s registration rights under this Section 1 shall expire at such time as all Registrable Securities
held by such Holder (together with any affiliates of such Holder with whom such Holder must aggregate its sales under Rule 144)
can be sold in any three (3) month period without registration under Rule 144.


 


1.14         
Limitations on Subsequent Registration Rights. From and after the date of this Agreement, the Company shall not, without
the prior written consent of the Holders of a majority of the Registrable Securities then outstanding (assuming conversion of all
Preferred Stock and exercise of the Common Warrants) and the approval of a majority of the Board of Directors, enter into any agreement
with any holder or prospective holder of any securities of the Company which would allow such holder or prospective holder to include
such securities in any registration filed under Section 1.3 hereof, unless under the terms of such agreement, such holder or prospective
holder may include such securities in any such registration only to the extent that the inclusion of his securities will not reduce
the amount of the Registrable Securities of the Holders which is included.


 






    12


     


    

 


2.              “Market
Stand-Off” Agreement. Each Holder hereby agrees that such Holder shall not sell, transfer, make any short sale of,
grant any option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a
sale of, any Common Stock (or other securities) of the Company held by such Holder (other than those included in the
registration) for a period specified by the representative of the underwriters of Common Stock (or other securities) of the
Company not to exceed one hundred eighty (180) days following the effective date of a registration statement of the Company
filed under the Securities Act in connection with the Company’s IPO (such period of time, the “Lockup
Period”), provided that all officers and directors of the Company and holders of at least one percent (1%) of
the Company’s voting securities (on an as-converted to Common Stock basis) are bound by and have entered into similar
agreements. The foregoing provisions of this Section 2 shall apply only to the IPO, and shall not apply to the sale of
any shares to an underwriter pursuant to an underwriting agreement, or any shares purchased in connection with the IPO or on
the open market following the IPO. Each Holder agrees to execute and deliver such other
agreements as may be reasonably requested by the Company or the underwriter which are consistent with the foregoing or which
are necessary to give further effect thereto. The Company may impose stop-transfer instructions with respect to the shares of
Common Stock (or other securities) subject to the foregoing restriction until the end of said one hundred eighty (180) day
period. The underwriters of the Company’s stock are intended third party beneficiaries of this Section 2 and shall have
the right, power and authority to enforce the provisions hereof as though they were a party hereto. Any discretionary waiver
or termination of the restrictions of any or all of such agreements by the Company or the underwriters shall apply pro rata
to all Company stockholders that are subject to such agreements, based on the number of shares subject to such
agreements.


 


3.            
Covenants of the Company.


 


3.1          
Delivery of Financial Statements to Investors. So long as an Investor holds at least 20,000,000 shares (as adjusted
for stock splits, combinations, reorganizations and the like) of Registrable Securities (a “Major Investor”),
the Company shall deliver to such Major Investor:


 


(a)               
as soon as practicable, but in any event within one hundred twenty (120) days after the end of each fiscal year of the
Company, an income statement for such fiscal year, a balance sheet of the Company and statement of stockholder’s equity as
of the end of such fiscal year, and a statement of cash flows for such fiscal year, such year-end financial reports to be in reasonable
detail, prepared in accordance with generally accepted accounting principles (“GAAP”) in the United States,
and audited and certified by independent public accountants of nationally recognized standing selected by the Board of Directors,
and accompanied by a certificate executed by the chief financial officer of the Company (in the event of no Company chief financial
officer then by the Chief Executive Officer) certifying that such financial statements fairly present the financial condition of
the Company and its results of operations for the periods specified therein; and


 


(b)              
as soon as practicable, but in any event within forty-five (45) days after the end of each of the first three fiscal
quarters of each fiscal year of the Company, an unaudited income statement, a statement of cash flows and an unaudited balance
sheet for such quarter, prepared in accordance with GAAP (except that such financial statements may (i) be subject to normal year-end
audit adjustments and (ii) not contain all notes thereto that may be required in accordance with GAAP), and accompanied by a certificate
executed by the chief financial officer of the Company (in the event of no Company chief financial officer then by the Chief Executive
Officer) certifying that such financial statements fairly present the financial condition of the Company and its results of operations
for the periods specified therein;


 


(c)               
as soon as practicable, but in any event thirty (30) days prior to the beginning of each fiscal year an annual budget
and operating plans for such fiscal year, prepared on a monthly basis, and, as soon as prepared, any other budgets or revised budgets
prepared by the Company;


 


(d)              
upon request, a detailed capitalization table of the Company; and


 






    13


     


    

 


(e)               
 upon the request of a Major Investor, such additional information and materials as the Major Investor may reasonably
request, and the Chief Executive Officer may consent to provide, such consent not to be unreasonably withheld, including documents
of the Company’s management, reports of operations, reports of adverse developments, copies of any management letters, and
stockholder communications.


 


3.2           Inspection.
The Company shall permit each Major Investor, at such Major Investor’s expense, to visit and inspect the Company’s
properties, to examine its books of account and records and to discuss the Company’s affairs, finances and accounts with
its officers, all at such reasonable times as may be convenient to the Company and such Major Investor; provided, however,
that the Company shall not be obligated pursuant to this Section 3.2 to provide access to any information that it reasonably considers
to be a trade secret or similar confidential information (unless covered by a confidentiality agreement, in form and substance
reasonably acceptable to the Company) or the disclosure of which would adversely affect the attorney-client privilege between
the Company and its counsel.


 


3.3           Confidentiality
of Records. Each Investor agrees to use the same degree of care as such Investor uses to protect its own confidential information
but in no event less than a reasonable degree of care, to keep confidential any information furnished to it that the Company identifies
as being confidential or proprietary (so long as such information is not in the public domain) and to keep confidential any confidential
information, knowledge or data concerning or relating to the business or financial affairs of the Company which such Investor
has been or shall become privy by reason of this Agreement, except that such Investor may disclose such proprietary or confidential
information (i) to any existing or prospective partner, affiliate (excluding portfolio companies), subsidiary, parent or member
of such Investor for the purpose of evaluating its investment in the Company as long as such existing or prospective partner,
affiliate (excluding portfolio companies), subsidiary, parent or member is advised of the confidentiality provisions of this Section
3.3 and is directed by such Investor to maintain the confidentiality of such information; (ii) to its attorneys, accountants,
consultants, and other professionals to the extent necessary to obtain their services in connection with monitoring its investment
in the Company, as long as such attorney, accountant, consultant or other professional is bound to the Investor to keep such information
confidential by industry standards or ethical rules (such as those applicable to attorney and accountants) or provisions at least
as stringent as those contained in this Section 3.3; (iii) to any prospective purchaser of any Registrable Securities from such
Investor, if such prospective purchaser agrees to be bound by the provisions of this Section 3.3; (iii) at such time as it enters
the public domain through no fault of such Investor; (iv) that is communicated to it free of any obligation of confidentiality;
(v) that is developed by Investor or its agents independently of and without reference to any confidential information communicated
by the Company; or (vi) as may otherwise be required by law, provided, however, that the Investor promptly notifies the
Company of such disclosure and takes reasonable steps to minimize the extent of any such required disclosure.


 


3.4          Right
of First Offer. Subject to the terms and conditions specified in this Section 3.4, the Company hereby grants to each Major
Investor a right of first offer with respect to future sales by the Company of its Shares. A Major Investor shall be entitled
to apportion the right of first offer hereby granted it among itself and its partners and affiliates in such proportions as it
deems appropriate; provided, that any such partner or affiliate shall, if not already a party, agree to become a party
to this Agreement as an “Investor” hereunder.


 


Each time following
the date hereof that the Company proposes to offer any shares of, or securities convertible into or exchangeable or exercisable
for any shares of, any class of its capital stock (“Shares”), the Company shall first make an offering
of such Shares to each Major Investor in accordance with the following provisions.


 






    14


     


    

 


(a)              The Company shall deliver a notice in accordance with Section 5.6 to the Major Investors stating (i) its bona fide
intention to offer such Shares, (ii) the number of such Shares to be offered, and (iii) the price and terms upon which it proposes
to offer such Shares.


 


(b)            
By written notification received by the Company, within fifteen (15) calendar days after delivery of the notice, the
Major Investor may elect to purchase or obtain, at the price and on the terms specified in the notice, up to that portion of such
Shares that equals the proportion that the number of shares of Common Stock deemed to be held by such Major Investor (including
all shares of Common Stock issuable or issued upon conversion of the Preferred Stock or upon the exercise of outstanding warrants
or options) bears to the total number of shares of Common Stock of the Company then outstanding (including all shares of Common
Stock issuable or issued upon conversion of the Preferred Stock or upon the exercise of outstanding warrants or options). The Company
shall promptly, in writing, inform each Major Investor that elects to purchase all the shares available to it (a “Fully-Exercising
Investor”) of any other Major Investor’s failure to do likewise. During the ten (10) day period commencing
after such information is given, each Fully-Exercising Investor may elect to purchase that portion of the Shares for which Major
Investors were entitled to subscribe but which were not subscribed for that is equal to the proportion that the number of shares
of Common Stock issued and held, or issuable upon conversion of Preferred Stock then held, by such Fully-Exercising Investor bears
to the total number of shares of Common Stock issued and held, or issuable upon conversion of the Preferred Stock then held, by
all Fully-Exercising Investors who wish to purchase some of the unsubscribed shares.


 


(c)           
If all Shares that Major Investors are entitled to obtain pursuant to Section 3.4(b) are not elected to be obtained
as provided in Section 3.4(b) hereof, the Company may, during the ninety (90) day period following the expiration of the period
provided in Section 3.4(b) hereof, offer the remaining unsubscribed portion of such Shares to any person or persons at a price
not less than, and upon terms no more favorable to the offeree than those specified in the notice. If the Company does not enter
into an agreement for the sale of the Shares within such period, or if such agreement is not consummated within ninety (90) days
of the execution thereof, the right provided hereunder shall be deemed to be revived and such Shares shall not be offered unless
first reoffered to the Major Investors in accordance herewith.


 


(d)           
The right of first offer in this Section 3.4 shall not be applicable to:


 


(i)                
the issuance of Series F Preferred Stock as part of the Financing;


 


(ii)              
the issuance of Common Stock upon the conversion of Convertible Securities (as defined in the Restated Certificate)
or shares of Preferred Stock, and capital stock issued pursuant to any such rights or agreements granted after the date of this
Agreement, so long as the rights of first offer established by this Section 3.4 were complied with, waived or inapplicable pursuant
to any provisions of this section 3.4(d);


 


(iii)            
shares of Common Stock issued or issuable by reason of a dividend, stock split, split-up or other distribution on shares
of Common Stock that is covered by Section 3(f) or Section 3(g) of Article FOURTH, Part C of the Restated Certificate and shares
of Common Stock issued or deemed issued as a dividend or Distribution (as defined in the Restated Certificate) on Preferred Stock;


 


(iv)              the
issuance of Common Stock and/or options, warrants or other Common Stock purchase rights and the Common Stock issued pursuant
to such options, warrants or other rights to employees, officers or directors of, or consultants or advisors to, the Company
or any subsidiary pursuant to stock purchase or stock option plans or other arrangements, the principal purpose of which is
other than the raising of capital through the sale of equity securities of the Company and the terms of which are approved by
the Board of Directors;


 






    15


     


    

 


(v)               
the issuance of shares of Common Stock or Convertible Securities to financial institutions, equipment lessors, landlords,
brokers or similar entities in connection with commercial credit arrangements, equipment financings, commercial property lease
transactions or similar transactions, the principal purpose of which is other than the raising of capital through the sale of equity
securities of the Company and the terms of which are approved by the Board of Directors;


 


(vi)             
the issuance of shares of Common Stock or Convertible Securities in connection with bona fide acquisitions, mergers
or similar transactions, the terms of which are approved by the Board of Directors;


 


(vii)           
shares of Common Stock issued or issuable upon the conversion of the Preferred Stock or the exercise of the Common Warrants;


 


(viii)         
shares of Common Stock issued or issuable pursuant to a Qualified Public Offering; or


 


(ix)             
shares of Common Stock or Convertible Securities issuable or issued to an entity as a component of any corporate strategic
relationship or transaction, the principal purpose of which is other than the raising of capital through the sale of equity securities
of the Company and which terms are approved by the Board of Directors.


 


(e)            
Notwithstanding the foregoing, the right of first offer in this Section 3.4 shall not be applicable to any Major Investor
with respect to any issuance of Shares if (i) at the time the Company issues such Shares, such Major Investor is not an “accredited
investor,” as defined in Rule 501(d) of Regulation D promulgated under the Securities Act, and (ii) such issuance of Shares
is only being offered by the Company to accredited investors.


 


3.5           Liability Insurance. The Company shall, at all times, maintain a directors’ and officers’ liability insurance
policy from a financially sound and reputable insurer with coverage limits reasonably acceptable to the majority of directors appointed
by the holders of Preferred Stock serving on the Board of Directors.


 


3.6           Stock
Vesting. Unless otherwise approved by the Board of Directors, all stock, stock options and other stock equivalents issued
after the date of this Agreement to employees, directors, consultants and other service providers shall be subject to vesting
as follows: (a) twenty-five percent (25%) of such stock shall vest at the end of the first year following the earlier of the date
of issuance or such person’s services commencement date with the Company, and (b) seventy-five percent (75%) of such stock
shall vest in equal monthly installments over the remaining three (3) years. With respect to any shares of stock purchased by
any such person still subject to vesting, the Company’s repurchase option shall provide that upon such person’s termination
of employment or service with the Company, with or without cause, the Company or its assignee shall have the option to purchase
at cost any unvested shares of stock held by such person. No stock option, restricted stock or similar equity grant to officers,
employees and consultants shall be transferable until such time as such stock option, restricted stock or similar equity grant
is fully vested.


 


3.7           Confidentiality
and Inventions Assignment Agreement. The Company shall require all employees to execute and deliver a Confidentiality and
Inventions Assignment Agreement substantially in a form approved by the Company’s counsel or Board of Directors and all
consultants to execute and deliver a consulting agreement containing reasonable provisions regarding the protection of the Company’s
confidential information and assignment of intellectual property created on behalf of the Company.


 






    16


     


    

 


3.8           Right of First Refusal. All shares of Common Stock of the Company shall be subject to a right of first refusal on all
transfers, which right shall be subject to the exemptions set forth in Article X, Sections 1(e) and 1(f) of the Company’s
Amended and Restated Bylaws. In the event the Company elects not to exercise any right of first refusal or right of first offer
the Company may have on a proposed transfer of any of the Company’s outstanding capital stock pursuant to the Company’s
charter documents, by contract or otherwise, the Company shall, to the extent it may do so, assign such right of first refusal
or right of first offer to each Major Investor. In the event of such assignment, each Major Investor shall have a right to purchase
its pro rata portion of the capital stock proposed to be transferred. Each Major Investor’s pro rata portion
shall be equal to the product obtained by multiplying (i) the aggregate number of shares proposed to be transferred by (ii) a fraction,
the numerator of which is the number of shares of Registrable Securities held by such Major Investor at the time of the proposed
transfer and the denominator of which is the total number of Registrable Securities owned by all Major Investors at the time of
such proposed transfer. If any Major Investors do not exercise in full this right of first refusal, the shares that would otherwise
be allocated to such non-fully exercising Major Investors shall be allocated among the fully exercising Major Investors wishing
to purchase the remaining shares (the “Over-Allotment”) on a pro-rata basis (calculated in the
same manner as above, provided, however, the denominator for purposes of such calculation shall be the total number of shares
held by all Major Investors participating in such Over-Allotment) up to the maximum shares specified by each such applicable Major
Investor. The Major Investors shall be entitled to apportion shares of Company capital stock purchasable hereunder among their
respective partners and affiliates in such proportions as they deem appropriate; provided, that any such partner or affiliate
shall, if not already a party, agree to become a party to this Agreement as an “Investor” hereunder.


 


3.9           Market Stand-off Restrictions. All capital stock issued by the Company, including any capital stock issuable or issued
upon exercise or conversion of any “Convertible Securities,” as defined in the Restated Certificate, shall be subject
to a market stand-off provision substantially similar to Section 2 of this Agreement.


 


3.10         Expenses Relating to Board Meetings. The Company shall promptly reimburse in full, each non-employee director of the
Company for all of his or her reasonable out-of-pocket expenses incurred related to attending meetings of the Company’s Board
of Directors or any committee thereof.


 


3.11         Board Approval. The Company hereby covenants and agrees with each of the Investors that it shall not, without approval
of the Board of Directors, which approval must include the affirmative vote of at least one of the directors appointed by the holders
of Preferred Stock:


 


(a)               
make, or permit any subsidiary to make, any loan or advance to, or own any stock or other securities of, any subsidiary
or other corporation, partnership, or other entity unless it is majority owned by the Company;


 


(b)              
make, or permit any subsidiary to make, any loan or advance to any person, including, without limitation, any employee
or director of the Company or any subsidiary, except advances and similar expenditures in the ordinary course of business or under
the terms of an employee stock or option plan approved by the Board of Directors;


 






    17


     


    

 


(c)               
 guarantee, directly or indirectly, or permit any subsidiary to guarantee, directly or indirectly, any indebtedness
except for trade accounts of the Company or any subsidiary arising in the ordinary course of business;


 


(d)              
incur any aggregate indebtedness in excess of $20,000 that is not already included in a budget approved by the Board
of Directors, other than trade credit or indebtedness to the Company incurred in the ordinary course of business;


 


(e)               
otherwise enter into or be a party to any transaction with any director, officer, or employee of the Company or any
 “associate” (as defined in Rule 12b-2 promulgated under the Exchange Act) of any such person, except for transactions
contemplated by this Agreement or the Financing, or transactions made in the ordinary course of business and pursuant to reasonable
requirements of the Company’s business and upon fair and reasonable terms that are approved by a majority of the Board of
Directors;


 


(f)                
hire, terminate, or change the compensation of the Chief Executive Officer;


 


(g)               
sell, assign, license, pledge, or encumber material technology or intellectual property, other than licenses granted
in the ordinary course of business;


 


(h)              
enter into any corporate strategic relationship involving the payment, contribution, or assignment by the Company or
to the Company of money or assets greater than $250,000; or


 


(i)                
enter into or joinder as a party to any transaction with any director or officer of the Company (other than for the
payment of salary and reimbursement of expenses made in the ordinary course of business), unless approved by a majority of the
directors who are disinterested in such transaction (with any interested director being required to recuse himself or herself).


 


3.12        Successor
Indemnification. If the Company or any of its successors or assignees consolidates with or merges into any other person and
is not the continuing or surviving corporation or entity of such consolidation or merger, then to the extent necessary, proper
provision shall be made so that the successors and assignees of the Company assume the obligations of the Company with respect
to indemnification of members of the Board of Directors as in effect immediately before such transaction, whether such obligations
are contained in the Company’s Amended and Restated Bylaws, its Restated Certificate, or elsewhere, as the case may be.


 


3.13        Investor
Form S-3 Registration Agreement. Following the closing of a Qualified IPO (as defined in the Restated Certificate), upon or
after the expiration of the Lockup Period, if the Company shall receive a written request from any Investor who may be deemed
an “affiliate” (as defined for this purpose in Rule 144), the Company agrees to enter into a Registration Rights Agreement,
in substantially the form attached hereto as Exhibit B, with such Investor. In the event any Registration Rights Agreement
is entered into, and any demand for registration is made pursuant thereto, it will be deemed to be a demand for registration pursuant
to the relevant section(s) of this Agreement for so long as such rights exist pursuant to this Agreement.


 


3.14        Termination
of Covenants. Except as set forth below, the covenants set forth in this Section 3 (other than Section 3.12) shall
terminate and be of no further force or effect upon the earlier of (a) the closing of a Qualified IPO; or (b) the
effective date of a Change of Control pursuant to which the Holders receive cash or securities traded on a nationally
recognized securities exchange. The covenants set forth in Sections 3.1 and 3.2 shall also terminate and be of no further
force or effect upon the Company becoming subject to the reporting provisions of the Exchange Act. Section
3.13 of this Agreement shall only terminate upon such time that such Investor, as reflected on the Company’s list of
stockholders, holds less than 1% of the Company’s outstanding Common Stock (treating all shares of Preferred Stock on
an as-converted basis), the Company has completed its IPO and all Registrable Securities of the Company issuable or issued
upon conversion of the Shares held by and issuable to such Investor may be sold pursuant to Rule 144 during any ninety (90)
day period.


 






    18


     


    

 


4.             Additional Covenants of the Parties.


 


4.1                FIRPTA. For so long as New Enterprise Associates 13, Limited Partnership; NEA Ventures 2009, Limited Partnership; KPCB
Holdings, Inc.; the Column Group, LP; ABG II-3V Limited; Rock Springs Capital Master Fund LP; Four Pines Master Fund LP; Baker
Brothers Life Sciences, L.P. and 667, L.P. (“Baker Brothers,” and each, individually, a “Participant”)
holds Preferred Stock of the Company or Registrable Securities, the Company shall provide prompt notice to the Participant, following
any “determination date” (as defined in United States Treasury Regulation Section 1.897-2(c)(1)) on which the
Company becomes a United States real property holding corporation. In addition, upon a written request by a Participant, the Company
shall provide the Participant with a written statement informing the Participant whether such Participant’s interest in the
Company constitutes a United States real property interest. The Company’s determination shall comply with the requirements
of Treasury Regulation Section 1.897-2(h)(1) or any successor regulation, and the Company shall provide timely notice to the
Internal Revenue Service, in accordance with and to the extent required by Treasury Regulation Section 1.897-2(h)(2) or any
successor regulation, that such statement has been made. The Company’s written statement to the Participant shall be delivered
to the Participant within 10 days of the Participant’s written request therefor. The Company’s obligation to furnish
such written statement shall continue notwithstanding the fact that a class of the Company’s stock may be regularly traded
on an established securities market or the fact that there is no preferred stock then outstanding.


 


4.2                Commerce
Department Compliance. The Company may be required to file reports with the Bureau of Economic Analysis (the “BEA”)
of the US Commerce Department when a US affiliate of a foreign Investor if such foreign Investor, together with its affiliates,
directly or indirectly controls ten percent (10%) or more of the voting securities of the Company. Such foreign Investor that
is a foreign individual or entity or a US subsidiary or affiliate of a foreign parent covenants to provide information necessary
for the Company to comply with BEA filings required under the International Investment and Trade in Services Act.


 


4.3                Indemnification Agreement. Immediately prior to the election or appointment of the Baker Brothers Director (as defined
in the Voting Agreement) to the Board of Directors, the Company shall enter into an Indemnification Agreement with the Baker Brothers
Director, in form reasonably approved by Baker Brothers.


 


4.4               Right
to Conduct Activities. The Company hereby agrees and acknowledges that SGMT Holdings Limited, Rock Springs Capital Master
Fund LP, Four Pines Master Fund LP, PFM Healthcare Master Fund, L.P. and Invus Public Equity, L.P. are professional
investment organizations, and as such reviews the business plans and related proprietary information of many enterprises,
some of which may compete directly or indirectly with the Company’s business (as currently conducted or as currently
propose to be conducted). The Company hereby agrees that, to the extent permitted under applicable law, SGMT Holdings
Limited, Rock Springs Capital Master Fund LP, Four Pines Master Fund LP, PFM Healthcare Master Fund, L.P. and Invus Public
Equity, L.P. shall not be liable to the Company for any claim arising out of, or based upon, (i) the investment by SGMT
Holdings Limited, Rock Springs Capital Master Fund LP, Four Pines Master Fund LP, PFM Healthcare Master Fund, L.P. and Invus
Public Equity, L.P. in any entity competitive with the Company, or (ii) actions taken by any partner, officer, employee or
other representative of SGMT Holdings Limited, Rock Springs Capital Master Fund LP, Four Pines Master Fund LP, PFM Healthcare
Master Fund, L.P. and Invus Public Equity, L.P. to assist any such competitive company, whether or not such action was taken
as a member of the board of directors of such competitive company or otherwise, and whether or not such action has a
detrimental effect on the Company; provided, however, that the foregoing shall not relieve (x) any of the
Investors from liability associated with the unauthorized disclosure of the Company’s confidential information obtained
pursuant to this Agreement, or (y) any director or officer of the Company from any liability associated with his or her
fiduciary duties to the Company.


 






    19


     


    

 


4.5               Qualified Small Business Stock. The Company agrees that for so long as any shares of Preferred Stock are held by an
Investor (or transferee) in whose hands such shares are eligible to qualify as “qualified small business stock” within
the meaning of Section 1202(c) of the Internal Revenue Code (the “Code”) it will (a) use best commercial
efforts to comply with any applicable filing and reporting requirements of Section 1202 of the Code and any regulations promulgated
thereunder; provided, however, that “best commercial efforts” as used in this section shall not be construed
to require the Company to operate its business in a manner which would adversely affect its business, limit its future prospects
or alter the timing or resource allocation of its planned operations or financing activities and (b) provide appropriate documentation
as to status with respect to “qualified small business stock” to each Investor that makes a request therefor within
ten (10) days of any such request.


 


5.             Miscellaneous.


 


5.1               Successors
and Assigns. Except as otherwise provided herein, the terms and conditions of this Agreement shall inure to the benefit of
and be binding upon the respective successors and assigns of the parties (including transferees of any shares of Registrable Securities).
Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective
successors and assigns any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly
provided in this Agreement.


 


5.2               Governing
Law. This Agreement shall be governed by the internal law of the State of Delaware, without regard to conflict of law principles
that would result in the application of any law other than the law of the State of Delaware.


 


5.3               Venue.
 Any suit or proceeding relating to, arising out of or arising under this Agreement shall be brought in the Delaware Court
of Chancery, which court shall have the sole and exclusive in personal, subject matter and other jurisdiction in connection with
such suit or proceedings and venue shall be appropriate for all purposes in such court.


 


5.4               Counterparts.
This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument. Counterparts may be delivered via electronic mail (including pdf or any
electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) or other transmission method and
any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.


 


5.5               Titles
and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not to be considered
in construing or interpreting this Agreement.


 


5.6               Notices.
All notices required or permitted hereunder shall be in writing and shall be deemed effectively given: (a) upon personal delivery
to the party to be notified; (b) when sent by confirmed electronic mail if sent during normal business hours of the recipient,
if not, then on the next business day; (c) five business days after having been sent by registered or certified mail, return receipt
requested, postage prepaid; or (d) one business day after deposit with a nationally recognized overnight courier, specifying next
day delivery, freight prepaid, with written verification of receipt. All communications to the Company shall be sent to:


 






    20


     


    

 


Sagimet Biosciences
Inc.


Attn: George
Kemble


155 Bovet
Road, Suite 303


San Mateo, CA 94402

George.Kemble@sagimet.com


 


with a copy (which
shall not constitute notice) to:


 


Cooley LLP


Attn: Carlton Fleming


3175 Hanover St.


Palo Alto, CA 94304

CFleming@cooley.com


 


All communications to
the Investors shall be made to their respective addresses (and with such copies, which shall not constitute notice) set forth in
Exhibit A attached hereto, or at such other address as any party may designate by 10 days advance written notice to the
other parties hereto.


 


5.7               Amendments
and Waivers. Any term of this Agreement may be amended and the observance of any term of this Agreement may be waived (either
generally or in a particular instance and either retroactively or prospectively), only with the written consent of the Company,
the Holders of a majority of the Registrable Securities then outstanding (assuming conversion of all Preferred Stock and exercise
of the Common Warrants) and the approval of a majority of the Board of Directors; provided, that the Schedule of Investors
attached as Exhibit A hereto may be amended by the Company without the consent of the Holders to include any additional
Holders of additional shares of Series F Preferred Stock sold and issued by the Company in any Additional Closing, as defined
in the Purchase Agreement; provided further, that any other section of this Agreement applicable to the Major Investors
may be amended, modified, terminated or waived only with the written consent of the Company and the holders of a majority of the
Registrable Securities then outstanding and held by the Major Investors; and provided further, that the consent of Baker
Brothers, SGMT Holdings Limited, Invus Public Equity, L.P., PFM Healthcare Master Fund, L.P., New Enterprise Associates 13, Limited
Partnership, KPCB Holdings, Inc., AP 11 Limited, Qianhai Ark (Cayman) Investment Co. Limited, Rock Springs Capital Master Fund
LP and Four Pines Master Fund LP shall be required to amend, modify, terminate or waive Section 3.1 in a manner that affects such
Investor, including, for the avoidance of doubt, the minimum number of shares necessary to be deemed a “Major Investor”
thereunder. Sections 3.13 and the last sentence of Section 3.14 may be amended, modified, terminated or waived only with the written
consent of the Company and Baker Brothers. Further, this Agreement may not be amended, and no provision hereof may be waived,
in each case, in any way that by its terms treats (a) a particular Investor in a disproportionately adverse manner relative to
the other Investors without such Investor’s written consent, or (b) a particular Major Investor in a disproportionately
adverse manner relative to the other Major Investors without such Major Investor’s written consent it being understood in
each instance that an Investor or Major Investor, as applicable, shall not be deemed to be treated differently because of the
proportional differences in the amounts of respective issue prices, liquidation preferences and redemption prices that arise out
of differences in the original issue price vis-à-vis other existing or future series of Preferred Stock. Notwithstanding
the foregoing, the Major Investors agree that a waiver of the provisions of Section 3.4 with respect to a particular transaction
shall be deemed to apply to all Major Investors in the same fashion if such waiver does so by its terms, notwithstanding the fact
that certain Major Investors may nonetheless, by agreement with the Company, purchase securities in such transaction, provided,
a Major Investor shall have the right to purchase its pro rata number of securities in such transaction, regardless of the waiver
of the provisions of Section 3.4, if any other Major Investor purchases in the same transaction. The Company will give reasonably
prompt notice of any amendment or termination hereof or waiver hereunder (other than a waiver by an Investor of only such Investor’s
rights hereunder) to any party hereto that did not consent in writing to such amendment, termination or waiver. Any amendment
effected in accordance with this Section 5.7 shall be binding upon each Holder of Registrable Securities of the Company.


 






    21


     


    

 


5.8               Severability.
If any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect, such provision will be
enforced to the maximum extent possible and such invalidity, illegality or unenforceability will not affect any other provision
of this Agreement. In such event, the parties shall negotiate, in good faith, a legal, valid and enforceable substitute provision
which most nearly effects the intent of the parties in entering into this Agreement.


 


5.9               Delays or Omissions. No delay or omission to exercise any right, power or remedy accruing to any party to this Agreement,
upon any breach or default of any party to this Agreement, shall impair any such right, power or remedy of such non-breaching or
non-defaulting party nor shall it be construed to be a waiver of any such breach or default, or an acquiescence therein, of or
in any similar breach or default thereafter occurring; nor shall any waiver of any single breach or default be deemed a waiver
of any other breach or default theretofore or thereafter occurring. Any waiver, permit, consent or approval of any kind or character
on the part of any party of any breach or default under this Agreement, or any waiver on the part of any party of any provisions
or conditions of this Agreement, must be in writing and shall be effective only to the extent specifically set forth in such writing.
All remedies, either under this Agreement or by law or otherwise afforded to any party, shall be cumulative and not alternative.


 


5.10              Entire Agreement. This Agreement constitutes the entire agreement between the parties hereto pertaining to the subject
matter hereof, and any and all other written or oral agreements relating to the subject matter hereof existing between the parties
hereto are expressly canceled.


 


5.11              Aggregation
of Stock.  All shares of Registrable Securities of the Company held or acquired by a stockholder and its affiliated entities
shall be aggregated together for the purpose of determining the availability of any rights under this Agreement.


 


5.12              Advice
of Counsel. EACH PARTY TO THIS AGREEMENT ACKNOWLEDGES THAT, IN EXECUTING THIS AGREEMENT, SUCH PARTY HAS HAD THE OPPORTUNITY
TO SEEK THE ADVICE OF INDEPENDENT LEGAL COUNSEL, AND HAS READ AND UNDERSTOOD ALL OF THE TERMS AND PROVISIONS OF THIS AGREEMENT.
THIS AGREEMENT SHALL NOT BE CONSTRUED AGAINST ANY PARTY BY REASON OF THE DRAFTING OR PREPARATION HEREOF.


 


[Signature
Pages Follow]


 






    22


     


    

 


IN WITNESS WHEREOF,
the parties have executed this Agreement as of the date first above written.


 


	 	COMPANY:
	 	 
	 	Sagimet Biosciences Inc.
	 	 
	 	By: 	/s/ George Kemble




	 	Name:	George Kemble
	 	Title:	Chief Executive Officer



 


SAGIMET
BIOSCIENCES INC


AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT


 







     


     


    

 


IN WITNESS WHEREOF,
the parties have executed this Agreement as of the date first above written.


	 	 
	 	INVESTORS:
	 	 
	 	667, L.P.
	 	 
	 	By: BAKER BROS. ADVISORS, LP, management company and investment adviser to 667, L.P., pursuant to authority granted to it by Baker Biotech Capital, L.P. general partner to 667, L.P., and not as the general partner




	 	 
	 	By:	 /s/ Scott Lessing




	 	Name:	Scott Lessing
	 	Title:	President
	 	 




	 	BAKER BROTHERS LIFE SCIENCES, L.P.
	 	 
	 	By: BAKER BROS. ADVISORS, LP, management company and investment adviser to Baker Brothers Life Sciences, L.P., pursuant to authority granted to it by Baker Brothers Life Sciences Capital, L.P. general partner to Baker Brothers Life Sciences, L.P., and not as the general partner
	 	 
	 	By:	/s/ Scott Lessing




	 	Name:	Scott Lessing
	 	Title:	President 




 


SAGIMET
BIOSCIENCES INC


AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT


 







     


     


    

 



 


IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above written.


 


		INVESTORS:
	 	 
	 	SGMT HOLDINGS LIMITED
	 	 
	              	By:	/s/ Colm O'Connell
	 	Name:	Colm O'Connell
	 	Title:	Authorized Signatory



 


Sagimet
Biosciences Inc.

Investor Rights Agreement 





 






     


     


    

 


IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above written.


 


	 	INVESTORS:
	 	 
	              	INVUS PUBLIC EQUITY,
    L.P.
	 	 
	 	By:	/s/
Raymond Debbane
	 	Name:	Raymond Debbane
	 	Title:	President of
its General Partner



 


Sagimet Biosciences
Inc.

Investor Rights Agreement


 






     


     


    

 


IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above written.


 


	 	INVESTORS:
	 	 
	 	PFM HEALTHCARE MASTER FUND, L.P.
	 	 
	              	By:	PFM Health Sciences, LP
	 	 
	 	By:	/s/ Yuan
    DuBord
	 	Name:	Yuan
    DuBord
	 	Title:	Chief
    Financial Officer



 


Sagimet
Biosciences Inc.

Investor Rights Agreement 


 






     


     


    

 


IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above written.


 





	              	INVESTORS:
	 	 
	 	ALTIUM GROWTH FUND, LP
	 	 
	 	 
	 	By:	/s/ Mark Gottlieb
	 	Name:	Mark Gottlieb
	 	Title:	COO



 


Sagimet
Biosciences Inc.

Investor Rights Agreement 


 






     


     


    

 


IN WITNESS WHEREOF,
the parties have executed this Agreement as of the date first above written.


  


	 	INVESTORS:
	 	 	 
	 	New Enterprise Associates 13, Limited Partnership
	 	 	 
		By:	NEA Partners 13, Limited Partnership
		Its:	General Partner
	 	 	 
		By:	NEA 13 GP, LTD
	           	Its:	General Partner



 





	              	By:	/s/ Louis Citron
	 	Name:	Louis Citron
	 	Title:	Chief Legal officer


 


	                  	NEA Ventures 2009, Limited Partnership




 


	 	By:	/s/ Louis Citron
	             	Name:	Louis Citron
	 	Title:	Chief Legal officer


 


SAGIMET
BIOSCIENCES INC.

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT


 






     


     


    

 


IN WITNESS WHEREOF,
the parties have executed this Agreement as of the date first above written.


 





	 	INVESTORS:
	 	 
	 	KPCB Holdings,
    Inc. as nominee
	              	 
	 	 
	 	By:	/s/ Susan Biglieri
	 	Name:	Susan Biglieri
	 	Title:	CFO



 


SAGIMET BIOSCIENCES INC.

 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT


 






     


     


    







 


IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above written.


 





	 	INVESTOR:
	 	 
	 	AP 11 Limited
	 	 
	              	 
	 	By:	/s/ Jinzi Jason Wu
	 	 	Name:	Jinzi Jason Wu
	 	 	Title:	CEO and President



 


SAGIMET
BIOSCIENCES INC.

INVESTORS’ RIGHTS AGREEMENT


 






     


     


    

 


IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above written.


 





	 	INVESTORS:
	 	 
	 	ROCK SPRINGS CAPITAL MASTER FUND LP
	 	 
	 	By:	Rock Springs General Partner LLC
	 	Its:	General Partner
	 	 
	              	By:	/s/ Kris Jenner
	 	Name:	Kris Jenner
	 	Title:	Member


 


Sagimet
Biosciences Inc.


Investor
Rights Agreement




 






     


     


    

 


IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above written.


 





	 	INVESTORS:
	 	 
	 	FOUR PINES MASTER FUND LP
	 	 
	 	By:	Four Pines General Partner LLC
	 	Its:	General Partner
	 	 
	 	By:	/s/ Kris Jenner
	              	Name:	Kris Jenner
	 	Title:	Member


 


Sagimet
Biosciences Inc.


Investor
Rights Agreement




 






     


     


    

 


IN WITNESS WHEREOF,
the parties have executed this Agreement as of the date first above written.


 





	 	INVESTOR:
	 	 
	 	Jason
Fuller
	 	 
	              	 
	 	By:	/s/ Jason Fuller
	 	 	Name:	Jason Fuller



 


Sagimet
Biosciences Inc.


Investors’
Rights Agreement




 






     


     


    

 


IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above written.


 





	 	INVESTORS:
	 	 
	 	 
	              	/s/ Tak Cheung
	 	Tak Cheung


 


Sagimet
Biosciences Inc.


Investors’
Rights Agreement




 






     


     


    

 


IN WITNESS WHEREOF,
the parties have executed this Agreement as of the date first above written.


 


	 	INVESTOR:
	 	 
	 	Suzhou Huimei Kangrui Management Consulting Partnership L.P.
	 	 
	 	(苏州惠每康瑞企业管理咨询合伙企业(有限合伙))
	 	 
	                          	By:	/s/ Rushu Luo
	 	 	Name: Rushu Luo
	 	 	Title: Managing Partner




 


Sagimet
Biosciences Inc.


Investors’
Rights Agreement




 






     


     


    

 


 









 


EXHIBIT A


 


SCHEDULE OF INVESTORS


 


	
        667, L.P.

        860 Washington St., 3rd Floor

        New York, NY 10014

         

	
        Baker Brothers Life Sciences, L.P.

        860 Washington St., 3rd Floor

        New York, NY 10014

         

	
        Altium Capital Management, LP

        152 W. 57th Street

        20th Floor

        New York, NY 10019

         

	
        AP11 Limited

        Vistra Corporate Services Centre, Wickhams Cay II,

        Road Town, Tortola, VG1110,
        British Virgin Islands

         

	
        SGMT Holdings Limited

        Walkers Corporate Limited

        Cayman Corporate Centre

        27 Hospital Road, George Town

        Grand Cayman KY1-9008, Cayman Islands

        Attn: Michael Yi and Ting Xie

        Email: myi@hillhousecap.com; txie@hillhousecap.com; legal@hillhousecap.com

         

        Necessarily including copies by email to the following:

         

        Goodwin Procter LLP

        The New York Times Building

        620 Eighth Avenue

        New York, NY 10018

        Attention to: Yash Rana; Chi Pan

        Email: yrana@goodwinlaw.com; 

        chipan@goodwinlaw.com

         

	
        Invus Public Equities, L. P.

        Attn. Raymond Debbane

        c/o The Invus Group, LLC

        750 Lexicon Ave.

        New York, New York 10022

         






 


Sagimet
Biosciences Inc.


Investors’
Rights Agreement


 






     


     


    

 


	
        PFM Healthcare Master Fund, L.P.

        c/o PFM Health Services, LP

        4 Embarcadero Center, Suite 3500

        San Francisco, CA 94111

        Attn: Darin Sadow, General Counsel

         

	
        Douglas Buckley

         

	
        Eric Meldrum

         

	
        GC&H Investments

        One California Street, 5th
        Floor

        San Francisco, CA 94111

        Attn: Jim Kindler

         

	
        G LTP LLC

        280 South Mangum Street

        Suite 210

        Durham, NC 27701-3984

         

	
        G ERP LLC

        280 South Mangum Street

        Suite 210

        Durham, NC 27701-3984

         

	
        G JBD LLC

        280 South Mangum Street

        Suite 210

        Durham, NC 27701-3984

         

	
        G HSP LLC

        280 South Mangum Street

        Suite 210

        Durham, NC 27701-3984

         






 


Sagimet
Biosciences Inc.


Investors’
Rights Agreement


 






     


     


    

 


	
        KPCB Holdings, Inc., as nominee

        Attn: Jesse King

        2750 Sand Hill Road

        Menlo Park, CA 94025

         

        with copies (which shall not constitute notice) to:

         

        Asher M. Rubin

        Hogan Lovells US LLP

        Harbor East

        100 International Drive, Suite 2000

        Baltimore, MD 21202

         

        Marcia Hatch

        Gunderson Dettmer LLP

        1200 Seaport Blvd

        Redwood City, CA 94065

         

	
        Merdad Parsey

         

	
        Michael C. Venuti

        

         

	
        New Enterprise Associates 13, Limited Partnership

        Attn: Louis Citron

        1954 Greenspring Drive 600

        Timonium, MD 21093

         

        with a copy (which shall not constitute notice) to:

         

        Asher M. Rubin

        Hogan Lovells US LLP

        Harbor East

        100 International Drive, Suite 2000

        Baltimore, MD 21202

         

	
        Jason Fuller

        700 12th ST NW STE 700 PMB 91438

        Washington DC 20005

         

	
        Tak Cheung

        

         

	
        Qianhai Ark (Cayman)
        Investment Co. Limited 

         






 


Sagimet
Biosciences Inc.


Investors’
Rights Agreement


 






     


     


    

 


	
        Rock Springs Capital
        Master Fund LP

        Attn: General Counsel

        650 S. Exeter Street, Suite
        1070

        Baltimore, MD 21202

         

        Send notices to:

        jill@rockspringscapital.com

        daphne@rockspringscapital.com

        ops@rockspringscapital.com

         

	
        Four Pines Master Fund
        LP

        Attn: General Counsel

        650 S. Exeter Street, Suite
        1070

        Baltimore, MD 21202

         

        Send notices to:

        jill@rockspringscapital.com

        daphne@rockspringscapital.com

        ops@rockspringscapital.com

         

	
        The Mendelson Family
        Trust

        Attn: Alan Mendelson

        140 Scott Place

        Menlo Park, CA 94025

         

	
        TriplePoint Ventures
        3, LLC

        2755 Sand Hill Road

        Menlo Park, CA 94025

         

	
        TriplePoint Ventures,
        LLC

        2755 Sand Hill Road

        Menlo Park, CA 94025

         

	
        Urs Greber

         

	
        VP Company Investments
        2004, LLC

        Attn: Alan Mendelson

        140 Scott Place

        Menlo Park, CA 94025

         

	
        Suzhou Huimei Kangrui Management Consulting Partnership L.P.
        

        Room112-11, Wuliu Building, No.88 Xiandai Avenue, Suzhou Industrial
        Park, Suzhou, China 215021

         



 


Sagimet
Biosciences Inc.


Investors’
Rights Agreement


 






     


     


    

 





EXHIBIT B


 


REGISTRATION RIGHTS
AGREEMENT